Mandate

Vinge advises Cellink in conjunction with the acquisition of Scienion Ag

Vinge has advised Cellink AB, listed on Nasdaq Stockholm, in connection with the acquisition of all shares in Scienion Ag. Scienion is a life science company which focuses on precision dimensioning technology.

The Scienion group conducts operations in Germany, the United States, France and England. The purchase price for the shares, on a cash‑free and debt‑free basis, amounts to EUR 80 million, of which EUR 40 million is paid in cash and the remaining EUR 40 million is paid in newly issued Cellink shares. Closing is expected to take place at the end of August whereupon Cellink’s board of directors will adopt a resolution concerning the issue in kind in accordance with the authorization resolved at the company’s general meeting. Cellink intends to perform a new issue of shares in order to finance the cash element of the purchase price.

Vinge’s team has consisted of, among others, Anders StridMartin E Svanberg (M&A), Edin Agic (Capital Markets) as well as Anna Palmérus (Competition Law). Hengeler Mueller advised Cellink in Germany.

Related

Vinge advises Trianon in connection with directed share issue and tender offer for subordinated sustainable capital securities

Vinge advises Fastighets Aktiebolaget Trianon (publ) in connection with a directed share issue of SEK 184 million and a tender offer for outstanding subordinated perpetual floating rate callable sustainable capital securities.
April 19, 2024

Vinge advises Blackstone in connection with its investment in Winthrop Technologies

Vinge, as local Swedish counsel, advised Blackstone Tactical Opportunities and affiliated funds (“Blackstone”) in connection with a strategic partnership with Winthrop Technologies Limited (“Winthrop Technologies”).
April 17, 2024

Vinge has advised Hansa Biopharma in connection with a directed share issue of SEK 372 million

Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of SEK 372 million before transaction costs. Hansa Biopharma is a commercial-stage biopharmaceutical company pioneering the development and commercialization of innovative, lifesaving and life altering treatments for patients with rare immunological conditions. Hansa Biopharma’s ordinary share is listed on Nasdaq Stockholm.
April 16, 2024